VRTXHey investors, this is a good opportunity to invest in VRTX under the fair valueLongby LukeMading2
Daily Squeeze PlayCarter's Squeeze Play setup. A daily squeeze has been building up for quite a few days. Which direction will it break to? Longby seariverunlimited3
$VRTX Clean set up.As easy as it gets. First target 240. (200DMA and 0,618 FIBO ext.) If market strong it will be able to blast through it.Longby TISSENBELGIUM1
Best Biotech to buy right now.Long-term investing. Probably one of the best ideas among the largest biotech companies. Buy @ $200-210, TP $300-500.Longby Heist_FlyZ4
$VRTX Vertex Short Idea (Bearish head and shoulders)Buy put spreads for April on this name. I think 180/165 put debit 4/19 would do well. XBI is under a lot of pressure, this company has nothing fresh right now, massive head and shoulders. Get it back in that safe channelShortby AlphaJiUpdated 5
$VRTX with a neutral outlook following its earnings #Stocks The PEAD projected a neutral outlook following a negative under reaction after its earnings release placing the stock in drift D If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us. by EPSMomentum0
VRTX Beginning!Fundamental & Chart Not for investment advice, personal notes only Chart: identified key area of support, concerning current H&S pattern, potential downside to next support indicate 17% drop. CMF shows weakness, spending a lot of times in the negatives. So far trend line remains intact, neckline of H&S shows no particular bearish inclination Fundamentals: Core product in strong growth, In January 26, 2021, VRTX announced that it received FDA approval for the use of Trikafta with children ages 6-11 with CF and certain mutations. In January 28, 2021, VRTX announced that it received FDA clearance for its type-1 diabetes investigational medicine and will enter the phase ½ clinical trial. Powerful toppling and bottom line growth, Net income has grown 229% from 2019 to September 2020. Currently seeking acquisition opportunities Let's wait and seeLongby jerryz73001221
Head and ShouldersPerfect. Will it work? Rarely does. However, we can track for posterity via TV. Let the games begin.Shortby frodo75Updated 113
$VRTX - Don't start buying just because Cathy woods isClear bearish trend....fundamentals might be right, but as a trader you need to focus on the trend. Shortby CheelooTrader1
(VRTX) Vertex - Upside potential ahead of Earnings releaseVertex is now at levels close to those of Dec'19. Meanwhile, revenues increased +60% QoQ for Q3 2020 and EPS increased + 20% (also QoQ for Q3 2020). Operational cashflows have improved as well. If expected annual earnings are confirmed, Vertex confirms its upside potential and has also a positive outlook ahead as a result of the current environment. Longby HR_DUpdated 6
$VRTX - 1D TA - Potential ReversalVRTX gets getting beat down by earnings but if this support lines hold true this was reverse and has a huge gap to fill. Keep in mind this in a Daily time frame and this will not happen over night (if it reverses). PS> Cathy Wood continues to buy VRTX so something could be coming. Do your own DD, this is not financial advice, only my idea. Longby rawsauceroc114
PullBack Fishing Symmetrical TriangleSymmetrical Triangles are a continuation pattern and can break either way.. Earnings 2-4 AMC Not a recommendation Keeping an eye on it tho (o:by lauralea111
$VRTX - Nice bear flagBearish pattern is emerging. Selling volume is still weak, but flush to 195 and 180 (VWAP) is likelyShortby CheelooTraderUpdated 112
Breakout of resistancewont be long before the stock breaks above the $237 resistance as it trades in the upward channel by Scotty-J0
Could vrtx fill the gap?VRTX has been inching closer to breaking out of its range state. With Biotech making new highs the stock should have flow tailwinds and any suppression of volatility in the market should be a positive. by IngenuityTrading1
VRTX - long term play - solid fundamentals - Ark has just boughtVRTX - long term play - solid fundamentals - Ark has just boughtLongby virtualtechie110
VRTX Gap Fill Play - Bullish- Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. - Target Price: $292.00 by CreditSuisse Oct 29, 2020 with multiple buy ratings by different analysts - Recent Drop from failed study of VX-814 for patients with ALPHA-1 ANTITRYPSIN DEFICIENCY, but still one more study going in same target area and fundamentals of other revenue makers intact. - Price entering the gap from that day's drop. - Trends of more insider buying since the drop and stock buy backs. Signaling that the stock is undervalued. - Bull flagging right under the gap. Key Level: $232.41 Price Target: 269.93 ATR: $6.60 Play: Bullish Gap Fill Buy the Dip under the key level to scale in Use $232.41 as inflection point. Look for breakout with increased volume Price Target: 270 Under $224 will invalidate Longby Pr0diJ1